Erythema nodosum induced by oral isotretinoin in a patient with condylomata acuminata

Erythema nodosum (EN) is a form of septal panniculitis, which is believed to represent a delayed hypersensitivity reaction activated by infectious agents, drugs, granulomatous and autoimmune diseases, pregnancy, and malignancies. There are only four reported cases of EN during oral isotretinoin therapy to our knowledge, all of them occurring in patients with severe acne. Since acne itself can trigger EN, the question as to whether there is indeed a causative relationship between isotretinoin and EN in the reported cases remains to be elucidated. We present herein a 20-year-old woman with multiple vulvar condylomata acuminata who developed EN two weeks after onset of oral isotretinoin therapy. To the best of our knowledge, this is the first report of EN occurring during isotretinoin treatment in a patient without acne and strongly indicates that the pathogenesis of EN can be directly related to the biological actions of isotretinoin. Erythema nodosum should be regarded as a rare side effect of oral isotretinoin therapy, regardless of the underlying disease. Physicians should be aware of this rare side effect

Topical imiquimod is and effective and safe drug for molluscum contagiosum in children

No abstract available.</p

Pyogenic Granuloma on Facial Skin Associated With Long-Term Topical Application of Tacrolimus: Pyogenic granuloma ans tacrolimus

Pyogenic granuloma (PG) is a benign vascular neoplasm of the skin and mucous membranes, the exact cause and pathogenesis of which still remain unknown. PG typically occurs in the form of solitary and rarely multiple, rapidly developing, glistering, hemorrhagic and ulceration-prone, pink or purple, angiomatous papule or nodule. Proposed stimuli for the occurrence of PG include minor trauma and chronic irritation, infections, viral oncogenes, pregnancy, microscopic arteriovenous anastomoses and diverse drugs. Tacrolimus is a macrolide, produced by the Streptomyces Ttsukubaensis, which exerts potent immunosuppressive action through inhibition of calcineurin. Topically applied tacrolimus has been approved for the treatment of patients with moderate to severe atopic dermatitis unresponsive or intolerant to conventional regimens, but it has also been used as an off-label treatment for various cutaneous diseases. We report a 35-year-old man who developed PG on his face after a long-term topical application of tacrolimus ointment for the treatment of seborrheic dermatitis. The patient didn’t recall any trauma or other chronic irritation at the site of his recently emerging solitary lesion, whereas other predisposing factors for PG were excluded. To the best of our knowledge the case presented here is the first report of this adverse reaction. PG should be considered as a possible side-effect of topical application of tacrolimus and dermatologists should be able to diagnose and properly treat it

Cutaneous Manifestations of Inflammatory Bowel Disease

Cutaneous lesions are among the most frequent extraintestinal manifestations of inflammatory bowel disease (IBD). They may precede, occur with or postdate the onset of the intestinal disease and can significantly contribute to the morbidity and impairment of the overall quality of life of the affected patients. In this article, the cutaneous manifestations of IBD are reviewed with particular emphasis on their clinicopathological and therapeutic aspects

Successful Treatment of Lichen Striatus With Occlusive Imiquimod 5% Cream

Lichen striatus is an uncommon acquired linear inflammatory skin disorder, that preferentially occurs in children. We report a 15-year-old girl with a 16-month history of lichen striatus. Topical application of imiquimod 5% cream twice-daily under occlusion led to resolution of the intense pruritus within 6 days of treatment and to complete remission of the cutaneous lesions after 5 weeks of treatment. The patient experienced no local or systemic side effects. She has been followed-up for 13 months and revealed no evidence of recurrence. Topical imiquimod may be an effective and safe alternative treatment for recalcitrant lichen striatus

Galectins 7 and 9 in Dermatology : Current knowledge and future perspectives

Galectins constitute a family of β-galactoside-binding proteins lectins that are widely distributed in nature occurring in mammals, sponges, fungi, nematodes, insects and viruses.  Galectins are involved in fundamental cellular processes in human skin and other tissues and exert biological effects of paramount importance through interactions with cytoplasmic and nuclear proteins and with components of cell surface and extracellular matrix, as well.In this paper we summarize current knowledge on the expression of galectins 7 and 9 in normal and diseased human skin and present the future perspectives of the use of these galectins or their antagonists/inhibitors in the diagnosis, prognosis and treatment of cutaneous disorders